RET and non-small cell lung carcinoma: Recently, in the phase 3 LIBRETTO-431 (NCT04194944) trial selpercatinib led to significantly longer progression-free survival than platinum-based chemotherapy with or without pembrolizumab in the first-line treatment of advanced RET-rearranged NSCLC [5].